pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
TROP-2 · news · pharmadog
← back to TROP-2
News · TROP-2
100
stories
8d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
8d
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
endpoints
12d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
12d
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 20, 26
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
Aug 4, 26
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 4, 26
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
Jul 29, 26
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 15, 26
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
biospace
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
May 14, 26
Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss
onclive
May 13, 26
Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
onclive
May 13, 26
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
onclive
May 13, 26
FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
onclive
May 13, 26
Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
onclive
May 13, 26
Future Directions in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Combination Radiopharmaceutical Approaches in Metastatic Castration-Resistant Prostate Cancer
onclive
← prev
page 1 of 4
next →
